Nyxoah's ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints

Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients

Reports an Apnea-Hypopnea Index (AHI) responder rate of 77.2% on a Full Analysis Set basis (p<0.001)

Zero device-related serious adverse events through 12 months